Brief: Affimed NV Expects Coronavirus Pandemic To Impact Clinical Trials
02/04/2020 12:12
April 2 (Reuters) - Affimed NV A28.F :
* AFFIMED NV SAYS PROVIDES UPDATE ON OPERATIONS IN RESPONSE
TO
CONTINUED SPREAD OF COVID-19 CORONAVIRUS PANDEMIC
* AFFIMED NV SAYS EXPECTS CORONAVIRUS PANDEMICWILL HAVE
IMPACT ON
CLINICAL TRIALS
* AFFIMED NV SAYS WILL UPDATE TRIAL TIMELINES AFTER MORE
VISIBILITY ON LENGTH AND EXTENT OF COVID-19 CRISIS
Source text for Eikon: ID:nGNXbKcMpG
Further company coverage: A28.F
(Reuters.Briefs@thomsonreuters.com)
Recent news on Affimed NV
See all newsBrief: Affimed Announces Receipt Of Nasdaq Delisting Notice
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million